Ciglitazone

C. Day, C. Bailey

Research output: Chapter in Book/Report/Conference proceedingEntry for encyclopedia/dictionary

Abstract

Ciglitazone was the first antidiabetic thiazolidinedione to be described in detail (Sohda et al., 1982). The thiazolidinediones (TZDs), also termed “glitazones”, activate the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Thiazolidinediones currently in clinical use for the treatment of type 2 diabetes are rosiglitazone (withdrawn in Europe in 2010) and pioglitazone. Another TZD, troglitazone, was withdrawn due to hepatotoxicity. Ciglitazone was not introduced into clinical use.
Original languageEnglish
Title of host publicationReference module in biomedical sciences
PublisherElsevier
ISBN (Print)978-0-12-801238-3
DOIs
Publication statusPublished - 2016

Fingerprint Dive into the research topics of 'Ciglitazone'. Together they form a unique fingerprint.

  • Cite this

    Day, C., & Bailey, C. (2016). Ciglitazone. In Reference module in biomedical sciences Elsevier. https://doi.org/10.1016/B978-0-12-801238-3.97236-2